This decision strengthens pfizer’s oncology franchise by moving an advanced. Enfortumab vedotin (also known as padcev and made by astellas) with pembrolizumab (also known as keytruda and made by msd) is. Padcev monotherapy provides clinical benefits in later treatment lines, with higher response rates than chemotherapy The fda approved padcev and keytruda for advanced bladder cancer in december 2023, following accelerated approval for. Padcev is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter, or urethra) Astellas pharma inc) in combination with pembrolizumab (keytruda
1 this regimen is specifically approved for use as neoadjuvant therapy and as adjuvant treatment after radical cystectomy (rc) in patients who are. Enfortumab vedotin (padcev) plus pembrolizumab (keytruda) has quickly moved to the forefront of treatment for advanced urothelial carcinoma This has raised questions about next lines of treatment and more Parminder singh, md, outlines current approaches to frontline decision making and options after disease progression.
OPEN
